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Synapse-protein (Aβ) is an invariable feature of Alzheimer's disease (AD); however, the
biological mechanism underlying Aβ assembly into ﬁbrils in the brain remains unclear. Here, we show that a
high-density cluster of GM1 ganglioside (GM1), which was detected by the speciﬁc binding of a novel peptide
(p3), appeared selectively on synaptosomes prepared from aged mouse brains. Notably, the synaptosomes
bearing the high-density GM1 cluster showed extraordinary potency to induce Aβ assembly, which was
suppressed by an antibody speciﬁc to GM1-bound Aβ, an endogenous seed for AD amyloid. Together with
evidence that Aβ deposition starts at presynaptic terminals in the AD brain and that GM1 levels signiﬁcantly
increase in amyloid-positive synaptosomes prepared from the AD brain, our results suggest that the age-
dependent high-density GM1 clustering at presynaptic neuritic terminals is a critical step for Aβ deposition
in AD.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionEvidence is accumulating that the interaction of amyloid β-protein
(Aβ) with lipid membranes is an early event in its ﬁbril formation in
Alzheimer's disease (AD) [1–3]. Previous in vitro studies suggested
that particular lipid constituents such as cholesterol can be a binding
partner for Aβ [4–6]. However, the nature of neuronal membranes
responsible for inducing Aβ assembly remains to be determined. We
previously identiﬁed GM1-ganglioside (GM1)-bound Aβ (GAβ) in the
brain that showed early pathological changes associated with AD [7,8].
To date, a number of in vitro and in vivo studies regarding GAβ have
supported the possibility that GAβ acts as an endogenous seed for
amyloid ﬁbril formation in the AD brain [9–17]. Yet despite the lines of
evidence in favor of this possibility, the GAβ hypothesis has been
challenged by a simple question concerning how GAβ is generated in
the AD brain.
To explore the mechanism underlying GAβ generation in the brain,
we previously examined the lipid composition of synaptosomes pre-
pared frommouse brains at different ages [18]. The prominent ﬁndings
in that study were as follows. First, the GM1 levels in detergent-
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l rights reserved.somes signiﬁcantly increased with age and the increase was markedly
pronounced in synaptosomes from the human apolipoprotein E4
(apoE4)-knock-in mouse brains comparedwith those from the apoE3-
knock-in mouse brains. Second, the DRMs possessed unique biochem-
ical features distinct from those of lipid rafts; for example, the GM1
accumulation in the DRMs was resistant to methyl-β-cyclodextrin
(MβCD) treatment, which is frequently used to destroy cholesterol-
and GM1-rich membrane microdomains such as lipid rafts [19,20].
Third, Aβ assembly to amyloid ﬁbril formation was markedly acce-
lerated in the presence of the synaptosomes bearing the DRMs. To-
gether with a previous ﬁnding that Aβ deposition likely starts at
presynaptic terminals in AD brains [21,22], these ﬁndings imply the
pathological signiﬁcance of GM1 accumulation at presynaptic neuritic
terminals in AD. Furthermore, this possibility has been supported by a
recent study showing that the GM1 levels signiﬁcantly increase in the
amyloid-positive synaptosomes comparedwith amyloid-free synapto-
somes prepared from AD brains [23].
The purpose of this studywas to clarify the nature of the GM1-rich,
MβCD-resistantDRMs (GMD).Here,we describe that GMD,with a high
potency to induce Aβ ﬁbril formation, selectively appeared in synap-
tosomes but not in non-synaptosomes prepared from mouse brains.
Importantly, the synaptosomes bearing the GMD were characterized
by their high-density GM1 clustering, which was speciﬁcally recog-
nized using a novel peptide (p3; VWRLLAPPFSNRLLP) [24]. Notably, the
high-density GM1 clustering in synaptosomes was an age-dependent,
and partially, brain-region-speciﬁc event. Finally, it was also suggested
that sphingomyelin (SM) plays a role in inducing the high-density GM1
clustering in presynaptic plasma membranes.
Fig. 1. Characterization of the synaptosomal and non-synaptosomal fractions. (A) Frac-
tions obtained from the preparation of the synaptosomal and non-synaptosomal
fractions were subjected to Western blot analysis using monoclonal antibodies speciﬁc
to SNAP25, syntaxin and nucleoporin p62. (B) The prepared synaptosomes were nega-
tively stained and examined by electron microscopy. Scale bar: 500 nm. (C) The synap-
tosomal and non-synaptosomal fractions obtained from four animals were subjected to
Western blotting assay using monoclonal antibodies speciﬁc to syntaxin and AQP4.
NP; nuclear pellet, PNS; post-nuclear supernatant, CMP; crude mitochondrial pellet,
nSPS; non-synaptosomal fraction, SPS; synaptosomal fraction, Wh: whole brain minus
the hippocampus, cerebellum and brainstem, Hp: hippocampus.
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2.1. Preparation of synaptosomes and non-synaptosomes
Synaptosomes were prepared as previously described [25,26]. A
hippocampus or awhole brainminus the hippocampus, cerebellum and
brainstem, was homogenized in 0.32 M sucrose buffer containing
0.25 mM EDTA. The homogenate was centrifuged at 580 ×g for 8 min.
The supernatant (post-nuclear supernatant) was centrifuged at
14,500 ×g for 20 min. The resulting pellet (crude mitochondrial pellet)
was suspended in 0.32 M sucrose buffer without EDTA, layered over
Ficoll in sucrose buffer, and then, centrifuged at87,000×g for 30min. The
resultant interface was collected as the source of synaptosomes. On the
other hand, the supernatant obtained by the centrifugation of the post-
nuclear supernatant was combined with the upper phase obtained by
the centrifugation of the suspension of the crude mitochondrial pellet,
and then, further centrifuged at 540,000 ×g for 30 min. The resultant
pellet was collected as the source of non-synaptosomes.
2.2. Electron microscopy
The synaptosomes isolated from brain homogenates were diluted
and then spread on carbon-coated grids, allowing each solution to stand
for 2 min before removing excess solution using a ﬁlter paper. After
drying, the grids were negatively stained with 2% uranyl acetate. Mic-
rographs were obtained by transmission electron microscopy using a
JEM-2000EX (JEOL, Tokyo, Japan) with an acceleration voltage of 100 kV.
2.3. Isolation of DRMs
The DRMs were prepared from the synaptosomes and non-
synaptosomes according to a previously established method [18].
Brieﬂy, synaptosomes (0.2 mg protein/ml) were homogenized inMES-
buffer saline (MBS) containing 1% Triton X-100. The sucrose con-
centration of the extract was adjusted to 40% by the addition of 80%
sucrose in MBS, and then they were overlaid with a 5%/35% discon-
tinuous sucrose gradient in MBS without Triton X-100, followed by
centrifugation at 188,000 ×g for 20 h using an SW41-Ti rotor (Beck-
man, Palo Alto, CA). After centrifugation, 1-ml fractions were har-
vested from the top to the bottom of the gradient. Success of DRM
isolation was veriﬁed by conﬁrmation of GM1 enrichment in the ﬁfth
fraction as had been reported in our previous study [18].
2.4. SDS-PAGE and Western blotting
The protein concentration of each sample was determined using a
BCA protein assay kit (Pierce, Rockford, IL) with bovine serum albumin
(BSA) as the standard. The samples were separated by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and then
electrotransferred onto NitroBind membrane (GE Osmonics, Minne-
tonka, MN). The blots were probed with, monoclonal antibodies spe-
ciﬁc to SNAP25, syntaxin, nucleaporinp62, aquaporin 4 (AQP4) or CTB-
HRP, which were purchased from Stressgen (Victoria, Canada), Santa
Cruz (CA, USA), BD Bioscience Pharmingen (CA, USA) Millipore (MA,
USA) and SIGMA-Aldrich (MO, USA), respectively. The bands were
visualized using an ECL detection system (GE Healthcare, Piscataway,
NJ).
2.5. Levels of sphingomyelin, GM1, phospholipids and cholesterol
The sphingomyelin levels in the samples were determined by TLC
and scanning densitometry. Lipids were extracted using chloroform/
methanol/water 52:26:21 by volume. The lower phase was removed,
and the solventwas evaporated and solubilized in chloroform/methanol
70:30 by volume. The lipid extract was spotted onto high-performance
TLC plates (Merck, Darmstadt, Germany) and run in three separatesolvent systems: methyl acetate/1-propanol/chloroform/methanol/
0.25% KCl solution 25:25:25:10:9 by volume; n-hexane/diethyl ether/
acetic acid 75:23:2 by volume; and n-hexane. After each run, the plate
was thoroughly dried using hot air. Lipid spots were visualized by
dipping the plates in a mixture of 10% CuSO4·5H2O, 8% H3PO4, then
placing them vertically on paper towels for 1 min to drain the excess
charring reagent, followed by heating for 10–20 min at 170 °C. Quan-
tiﬁcation was performed using NIH image version 1.59 software. The
GM1 level in the samples was determined by blot analysis using cholera
toxin B subunit-horseradish peroxidase conjugated (CTX-HRP) as
previously reported [7]. The cholesterol and phospholipid levels in the
sampleswere determinedusingDeterminer L (Kyowa, Tokyo, Japan) and
Phospholipids C (Wako, Osaka, Japan), respectively.
2.6. Aβ incubation in the presence of synaptosomes
Seed-free solutions of Aβ (Aβ1–40) (Peptide Inst., Osaka, Japan)
were prepared as previously described [27]. Aβ solutions at 50 μM in
Tris-buffered saline (TBS1: 10 mM Tris–HCl and150 mM NaCl, pH 7.4)
were incubated at 37 °C with or without synaptosomes. The ﬂuo-
rescence intensities of Thioﬂavin T (ThT), which speciﬁcally recognizes
the amyloid structure, of the mixture incubated for 24 h were deter-
mined as previously described [15].
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The synaptosomes were washed with Tris-buffered saline (TBS2;
20mM Tris–HCl, 150 mMNaCl, pH 7.4) at 4 °C and then resuspended in
TBS2with orwithout 10mMMβCD. After incubation at 37 °C for 30min,
the mixture was centrifuged at 17,000 ×g for 15 min. The resultant
precipitates were subjected to assay or fractionation for DRMs.
2.8. Fluorescence staining of GM1 clustering
Synaptosomes and non-synaptosomes were seeded on poly-L-
lysine-coated 24-well plates at a total protein content of 3 μg and
incubated either with or without biotin-conjugated p3 (VWRLLAP
PFSNRLLP, 300 nM) at room temperature for 1 h. After washing
with PBS, the synaptosomes were incubated with Alexa Fluor 594-
conjugated streptavidin (10 μg/ml) for 1 h. The synaptosomes incu-
bated alone with Alexa Fluor 594-conjugated streptavidin without
p3 treatment did not show labeling.
2.9. Inhibition of membrane-bound neutral sphingomyelinase
PC12 cells were cultured in Dulbecco's modiﬁed Eagle's medium
(DMEM, Invitrogen, Carlsbad, CA) supplemented with 10% heat-
inactivated horse serum and 5% FBS. For their differentiation, PC12
cells were plated on poly-L-lysine-coated (10 mg/ml) chamber slides
(Nunc, Roskilde, Denmark) at a density of 50,000 cells/cm2 and cul-
tured for 6 days in DMEM supplementedwith 100 ng/ml nerve growth
factor (NGF; Alomone Labs, Jerusalem, Israel). The cells were treated
with GW4869 (Calbiochem, Darmstadt, Germany). After 2 days, the
cells were ﬁxed with 4% formaldehyde and incubated with 5% BSA
blocking agent. The cells were then incubated with biotin-conjugatedFig. 2. GM1 accumulates in MβCD-treated synaptosomes prepared from aged mouse brain. T
old) and aged (2-year-old) mouse brains with or without MβCD treatment are shown. Each
from mouse brain. The GM1 levels were determined by densitoscanning the blot follow
MβCD treatment are indicated. Each column indicates the average of eight values±S.D.
SPS; synaptosome fraction, nSPS; non-synaptosome fraction, Wh: whole brain minus the hp3 and Alexa Fluor 488-coupled CTX at room temperature for 1 h.
After washing with PBS, the cells were incubated with Alexa Fluor
594-conjugated streptavidin (10 μg/ml) for 1 h.
3. Results
3.1. Characterization of synaptosomes and non-synaptosomes
The isolated synaptosomes were characterized by Western blot
analysis using monoclonal antibodies speciﬁc to SNAP-25 and syntaxin,
which are abundant in presynaptic plasmamembrane, and nucleoporin
p62, which exclusively localizes at the nuclear membrane [28]. As
shown in Fig. 1A, the presynaptic marker proteins were abundant in the
synaptosome fractions whereas the nuclear proteinwas absent in these
fractions. Moreover, electron microscopy of the synaptosome fractions
revealed typical structural characteristics of synaptosomes with the
presence of recognizable mitochondria (Fig. 1B). To compare the char-
acteristics of the isolated synaptosomes and non-synaptosomes, we
performed Western blot analysis using monoclonal antibodies speciﬁc
to syntaxin andAQP4,which is exclusively abundant in astrocyte plasma
membrane [29]. As shown in Fig. 1C, the presence of syntaxin and AQP4
in the synaptosomes and non-synaptosomes were mutually exclusive.
3.2. Characterization of GM1 accumulation in synaptosomes
We characterized the GM1 accumulation in synaptosomes and
non-synaptosomes using MβCD which can potently break down
cholesterol- and GM1-rich DRMs such as lipid rafts by removing
cholesterol. Synaptosomes and non-synaptosomes were prepared
from whole brain minus hippocampus, cerebellum and the brain-
stem, and the hippocampus of two different age groups of mice (4-he GM1 levels of synaptosomes and non-synaptosomes prepared from young (4-week-
lane of the blot contains 1 μg of synaptosomes or non-synaptosome protein prepared
ing incubation with CTX-HRP. The intensities of the bands relative to those without
⁎pb0.01, ⁎⁎pb0.001, ⁎⁎⁎pb0.0001 (one-way ANOVA combined with Scheffe's test).
ippocampus, cerebellum and brainstem, Hp: hippocampus.
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synaptosomes, which were determined by the speciﬁc binding of
CTX-HRP, were higher in the samples prepared from agedmouse brains
than those from young mouse brains (Fig. 2). Notably, the GM1
accumulation in non-synaptosomes prepared from aged mouse brains
markedly decreased following MβCD treatment whereas that in
synaptosomes prepared from the same brains was resistant to MβCD
treatment (Fig. 2). Although the extent of the GM1 accumulation was
lower in the samples prepared fromyoungmouse brains than fromaged
mouse brains, the resistance of GM1 accumulation to MβCD treatment
was consistently observed in synaptosomes prepared from the hip-
pocampus but not from thewhole brain (Fig. 2). The levels of cholesterol
markedly decreased in synaptosomes and non-synaptosomes from
mouse brains of both age groups following MβCD treatment and the
decrease in the levels of total phospholipids following MβCD treatment
was moderate compared with that of cholesterol (data not shown).
To further characterize the resistance of GM1 showing age-
dependent accumulation in the synaptosomes to MβCD treatment,
we isolated DRM fractions from the synaptosomes and non-synapto-
somes. The successful DRM isolation was conﬁrmed by the observa-
tion of GM1 abundance in the fractions as was previously reported
(Fig. 3A). We then compared the resistance of GM1 accumulation to
MβCD treatment in each fraction between the synaptosomes and non-Fig. 3. GM1 accumulates in DRM isolated from MβCD-treated synaptosomes of aged mo
fractionation were subjected to blot analysis using CTX-HRP. (B) The blot of DRM isolated fro
with or without MβCD treatment, which was probed with CTX-HRP, is shown. The chole
Phospholipids C, respectively. Each column indicates the average of three values±S.D. ⁎p
nSPS; non-synaptosome fraction, Wh: whole brain minus the hippocampus, cerebellum ansynaptosomes. Following MβCD treatment, the decrease in GM1 level
in the DRM fractions prepared from synaptosomes (arrow a in Fig. 3B)
was apparently less than that of the DRM fractions prepared from
non-synaptosomes (arrow b in Fig. 3B). MβCD treatment markedly
decreased the cholesterol levels, and the levels of total phospholipids
also decreased following MβCD treatment but it was less than the
decrease in cholesterol levels (Fig. 3B).
3.3. Aβ ﬁbril formation in the presence of the synaptosomes or the DRMs
prepared from synaptosomes
We determined whether the GM1 accumulation in the synapto-
somes accelerates Aβ assembly into amyloid ﬁbrils. We ﬁrst incubated
soluble Aβ in the presence of the synaptosomes prepared from three
different age groups of mice (4-week-old, 1-year-old and 2-year-old
groups). The ThT ﬂuorescence intensity in the incubated mixtures
increased in an age-dependent manner (Fig. 4A). Notably, the increase
in ThT ﬂuorescence intensity was signiﬁcantly suppressed by coin-
cubation with 4396C, an antibody speciﬁc to GAβ, suggesting that
amyloid ﬁbril formation in the presence of synaptosomes occurred
through GAβ generation. We then incubated soluble Aβ1–40 in the
presence of the synaptosomes or non-synaptosomes from agedmouse
brain with or without MβCD pretreatment. The ThT ﬂuorescence inuse brain. (A) Fractions obtained by DRM isolation through sucrose density gradient
m synaptosomes and non-synaptosomes prepared from aged (2-year-old) mouse brain
sterol (CH) and phospholipids (PLs) levels were determined using Determiner L and
b0.0001 (one-way ANOVA combined with Scheffe's test). SPS; synaptosome fraction,
d brainstem, Hp: hippocampus.
Fig. 4. Aβ assembly in the presence of DRM isolated from synaptosomes of aged mouse brain. (A) The ThT ﬂuorescence intensity of the incubation mixtures containing Aβ incubated
at 50 μM and 37 °C for 24 h in the presence or absence of synaptosomes prepared from brains of three different age groups of mice with or without 4396C is shown. (B) The ThT
ﬂuorescence intensity of the incubation mixtures containing Aβ incubated at 50 μM and 37 °C for 24 h in the presence or absence of synaptosomes or non-synaptosomes prepared
from agedmouse brainwith or without 4396C is shown. The synaptosomes and non-synaptosomes had been pretreated with or without MβCD. (C) The ThT ﬂuorescence intensity of
the incubationmixtures containing Aβ incubated at 50 μMand 37 °C for 24 in the presence or absence of DRM isolated from synaptosomes or non-synaptosomes of agedmouse brain
with or without 4396C or CTX is shown. Each column indicates the average of four values±S.D. ⁎pb0.001, ⁎⁎pb0.0001 (one-way ANOVA combined with Scheffe's test).
SPS; synaptosome fraction, nSPS; non-synaptosome fraction, Wh: whole brain minus the hippocampus, cerebellum and brainstem, Hp: hippocampus.
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increased compared with that in the incubation mixtures containing
non-synaptosomes (Fig. 4B). Again, the increase in the ThT ﬂuores-
cence intensity was signiﬁcantly suppressed by coincubation with
4396C. Importantly, the increase in the ThT ﬂuorescence intensity of
the incubation mixture was not suppressed by MβCD pretreatment
(Fig. 4B).We then investigated whether the potency of synaptosomes to
accelerate Aβ assembly is attributed to the DRMs. We incubated
soluble Aβ1–40 in the presence of the isolated DRMs from synapto-
somes or non-synaptosomes of aged mouse brain. The ThT ﬂuores-
cence intensity signiﬁcantly increased in the incubation mixtures
containing the DRMs isolated from synaptosomes but not from non-
synaptosomes (Fig. 4C). Again, the increase in the ThT ﬂuorescence
2722 N. Yamamoto et al. / Biochimica et Biophysica Acta 1778 (2008) 2717–2726intensity was signiﬁcantly suppressed by coincubation with CTX or
4396C (Fig. 4C), indicating that amyloidﬁbril formation in the presence
of DRMs is GM1-dependent and GAβ-mediated.
3.4. High-density GM1 clustering on synaptosomes
To further characterize the GM1 accumulation on the surface of
synaptosomes, particularly from the viewpoint of GM1 clustering, weFig. 5. Peptide p3 binds to synaptosome from aged mouse brain. (A) Proposed scheme for
prepared from young (4-week-old) and aged (2-year-old) mouse brains were incubated wit
(C) The number of p3-bound spots shown in (B) was determined. Each column indicates the
ND: not detected. SPS; synaptosome fraction, nSPS; non-synaptosome fraction, Wh: wholeincubated the synaptosomes prepared from whole brain and hip-
pocampus of young and aged mouse brains with a novel peptide (p3),
which speciﬁcally recognizes the high-density GM1 clustering
(Fig. 5A). The p3 binding was extremely restricted to synaptosomes
and no binding was detected on non-synaptosomes (Fig. 5B). Im-
portantly, the levels of p3 binding to synaptosomes prepared from
aged mouse brains was signiﬁcantly higher than those of p3 binding
to synaptosomes prepared from young mouse brains (Fig. 5B, C).the speciﬁc p3 binding to GM1 clusters. (B) The synaptosomes and non-synaptosomes
h biotin-conjugated p3 then with Alexa Fluor 594-conjugated streptavidin. Bar, 50 μm.
average of four values±S.D. ⁎pb0.0001 (one-way ANOVA combined with Scheffe's test).
brain minus the hippocampus, cerebellum and brainstem, Hp: hippocampus.
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young mouse brains, the p3 binding was only observed in those pre-
pared from hippocampus but not from whole brain (Fig. 5B, C).
3.5. Age-dependent sphingomyelin accumulation in synaptosomes
To explore a possiblemechanismof the age-dependent high-density
GM1 clustering in synaptosomes, we examined the lipid composition
of synaptosomes prepared from three different age groups of mice (4-
week-old,1-year-old and2-year-old groups). Signiﬁcantly, the SM levels,
which were determined by thin-layer chromatography (TLC), increased
with age in synaptosomes prepared from both whole brain and hip-
pocampus (Fig. 6). The GM1 level in synaptosomes also increased with
age but to a lesser extent than the increase in SM level, whereas the
levels of cholesterol and total phospholipids in synaptosomes remained
unchanged, except a decrease in the cholesterol content in the synap-
tosomes prepared from hippocampus, with age, respectively (Fig. 6).
Then, to further characterize the age-dependent SMaccumulation in the
synaptosomes, we isolated DRMs from the synaptosomes and non-
synaptosomes prepared from whole brain minus hippocampus, cere-
bellum and brainstem, and the hippocampus of agedmouse brains. The
SM level was signiﬁcantly higher in the DRMs isolated from synapto-
somes than in those isolated from non-synaptosomes (Fig. 7). Enrich-Fig. 6. Aging induces SM and GM1 accumulation in synaptosomes. The lipid composition of sy
levels were determined by densitoscanning the TLC plate. The intensities of the bands relat
densitoscanning the blot incubated with CTX-HRP. The intensities of the bands relative to th
Determiner L and Phospholipids C, respectively. Each column indicates the average of eight v
test). Wh: whole brain minus the hippocampus, cerebellum and brainstem, Hp: hippocampment in the DRMs isolated from synaptosomes was not observed with
GM1, cholesterol and total phospholipids (Fig. 7).
3.6. Induction of high-density GM1 clustering at neuritic terminals
through sphingomyelinase inhibition
To obtain direct evidence that SM is involved in the induction of
high-density GM1 clustering, we incubated PC12 cells, which were
induced to differentiate with nerve growth factor, with GW4869,
which speciﬁcally inhibits plasma-membrane-bound neutral sphin-
gomyelinase (nSMase). The SM levels following nSMase inhibition
signiﬁcantly increased whereas the GM1 levels apparently remained
unchanged with the treatment (Fig. 8A). Notably, the p3 binding was
speciﬁcally observed at neuritic terminals of the PC12 cells, and it was
only observed when the cells were pretreated with GW4869. In con-
trast, the CTX binding at the neuritic terminals was consistently ob-
served regardless of GW4869 pretreatment of the cells (Fig. 8B).
4. Discussion
A previous in vitro study using liposomes clearly showed that
GM1-mediated Aβ ﬁbril formation through GAβ generation signiﬁ-
cantly depends on the GM1 distribution but not merely on the GM1naptosomes prepared frommouse brains of three different age groups is shown. The SM
ive to those of the 4-week-old mice are indicated. The GM1 levels were determined by
ose of the 4-week-old mice are indicated. The CH and PLs levels were determined using
alues±S.D. ⁎pb0.05, ⁎⁎pb0.005, ⁎⁎⁎pb0.001 (one-way ANOVA combined with Scheffe's
us.
Fig. 7. Lipid composition of DRM isolated from synaptosomes. The lipid composition of DRM isolated from synaptosomes and non-synaptosomes prepared from aged (2-year-old)
mouse brain is shown. The SM and GM1 levels were determined by densitoscanning the TLC plate and the blot incubated with CTX-HRP, respectively. The intensities of the bands
relative to those of synaptosomes are indicated. The CH and PLs levels were determined using Determiner L and Phospholipids C, respectively. Each column indicates the average of
four values±S.D. ⁎pb0.001 (one-way ANOVA combined with Scheffe's test). SPS; synaptosome fraction, nSPS; non-synaptosome fraction, Wh: whole brain minus the hippocampus,
cerebellum and brainstem, Hp: hippocampus.
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facilitated in the presence of GM1 clusters [13]. Thus, it is a challenge
to determine how the GM1 clustering, to the extent that it accelerates
GAβ generation, occurs on neuronal membranes under biological
conditions. In this study, taking advantage of the speciﬁc binding of a
novel peptide, p3, to high-density GM1 clusters [24,30], we success-
fully showed that the high-density GM1 clusters, which potently
induce Aβ ﬁbrillogenesis, appeared with age at presynaptic terminals
in the brain. This study also suggested that the age-dependent SM
accumulation is involved in the high-density GM1 clustering at pre-
synaptic terminals. Our results may provide a new insight into the
biological mechanism of Aβ assembly into ﬁbrils in the AD brain.
The novel peptide, p3, has recently been selected from a phage-
displayed random peptide library using air–water interface mono-
layers [24]. From the Hill plot analysis, it was shown that p3 likely has
two binding sites that work cooperatively, indicating that the peptide
p3 simultaneously binds to two GM1 molecules that stand very close
to each other [24]. This is in good contrast to the binding feature of
CTX to GM1, where CTX has a single binding site that works non-
cooperatively and equally to a single GM1 molecule regardless of its
standing whether solitary or in cluster [24]. Although it remains to be
clariﬁed how the high-density GM1 clustering provides a favorable
microenvironment for GAβ generation, it may be assumed that the
alteration of GM1 lateral distribution affects the spatial arrangement
of the oligosaccharide chain (head-group) of the GM1 molecule [31].
One of the striking ﬁndings of this study is that the high-density
GM1 clustering was exclusively observed in synaptosomes but not innon-synaptosomes. To the best of our knowledge, no study has ever
compared the lipid composition of DRMs, particularly the GM1 level,
between synaptosomes and non-synaptosomes. Further studies are
required; however, the GM1 turnover at presynaptic neuritic ter-
minals may be different from that at other neuronal membranes. The
result of our recent study is in line with this possibility. That is, the
endocytic pathway abnormality that was induced by treatment of
PC12 cells with chloroquine, a weak base, facilitated the GM1-induced
Aβ ﬁbrillogenesis selectively at presynaptic neuritic terminals [32]
regardless of the broad distribution of GM1 throughout the cell body
and neurites [33]. Alternatively, the GM1 distribution at presynaptic
neuritic terminals may be modiﬁed by other membrane constituents.
In this context, this study showed that SM preferably localized in the
DRMs prepared from synaptosomes compared with in those from
non-synaptosomes. It is also interesting to note that the maturation of
the axonal plasma membrane is associated with increasing SM levels
in DRMs [34]. Furthermore, in terms of the MβCD resistance of the
GMD, a previous study suggested that the SM level in a given mem-
brane plays a critical role in the retention of cholesterol against the
efﬂux induced byMβCD [35]. This line of evidence suggests that SM at
presynaptic plasmamembranes, the level of which increases with age,
is involved in the formation of unique membrane microdomains such
as the GMD. A previous study also suggested that cholesterol plays a
critical role in the formation of GMD, which is responsible for GAβ-
induced Aβ assembly [13]. However, we did not observe an age-
dependent increase in the cholesterol level in synaptosomes as
previously reported [36,37]. At present, the reason for the discrepancy
Fig. 8. High-density GM1 clustering at neuritic terminals through sphingomyelinase inhibition. (A) PC12 cells were treated with GW4869 at the indicated concentrations for 2 days.
The SM and GM1 levels were determined by densitoscanning the TLC plates and the blot incubated with CTX-HRP, respectively. The intensities of the bands relative to those of the
control are indicated. Each column indicates the average of four values±S.D. ⁎pb0.01, ⁎⁎pb0.001 (one-way ANOVA combinedwith Scheffe's test). (B) Fluorescence image of GW4869-
treated or untreated PC12 cells with CTX (green) and p3 (red) is shown. Arrows indicate the neuritic terminals of PC12 cells. Bar, 100 μm.
2725N. Yamamoto et al. / Biochimica et Biophysica Acta 1778 (2008) 2717–2726in results between this study and previous studies remains unclear.
Studies in the future should clarify whether cholesterol level in
synaptosomes can be affected by age and other various factors such as
feed, and also whether its age-dependent alteration can inﬂuence the
formation of GMD in the brain.
Although this study was limited to the hippocampus and whole
brain minus the hippocampus of mouse brains, the favorable ap-
pearance of high-density GM1 clusters in the hippocampus may imply
its pathological signiﬁcance because the hippocampus is an invariably
preferable region for Aβ deposition in various transgenicmouse brains
[38–40]. Our previous study using cultured primary neurons showed
that the lipid composition and lipid requirement for differentiation
were different between hippocampal neurons and cortical neurons;
that is, the cholesterol levels of hippocampal neurons are signiﬁcantly
higher than those of cortical neurons [41]. The implication of this
study to address the pathophysiology of AD is limited because our datawere obtained only from animals; however, this study may raise
particular concerns on the signiﬁcance of the alteration of the com-
position and distribution of lipids, including GM1, SM and choleste-
rol at presynaptic plasma membranes in relation to the initiation of
amyloid pathology associated with AD.
In summary, our results suggest that high-density GM1 clustering,
which markedly induces Aβ assembly, occurs in presynaptic neuritic
terminals in the brain in age-dependent, and partially, brain-region-
speciﬁcmanners. It was previously reported that Aβ deposition starts at
the presynaptic neuritic terminals in AD brain [21,22] and that the GM1
levels signiﬁcantly increase in the DRMs [42] and also in amyloid-
positive synaptosomes prepared fromADbrain [23].With this evidence,
our results suggest that the age-dependent GM1 accumulation to its
high-density clustering inpresynaptic neuritic terminals is a critical step
for Aβ deposition in AD. Recently, accumulated evidence has indicated
that amyloid ﬁbril formation fromvarious amyloidogenic proteins other
2726 N. Yamamoto et al. / Biochimica et Biophysica Acta 1778 (2008) 2717–2726thanAβ, including IAPP, prion protein, calcitonin and SAA, is accelerated
through their interactionwith biomembranes, conversely, the biomem-
brane structure is likely affected by amyloid growth [43–48]. This study
may also provide a novel insight into molecular pathogenesis common
among various amyloid-generating diseases.
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